Recent developments in biosensor based transdermal drug delivery systems

Abstract

In recent years, transdermal drug delivery systems (TDDS) have grown significantly owing to their numerous advantages over traditional oral medications. According to recent reports, the transdermal drug delivery market has a global projection of approximately US$ 8.7 billion by 2027, with a compound annual growth rate (CAGR) of 6.39% during 2021–2027. The primary concern with oral and injectable drug administration is the risk of overdosing due to fluctuating peak plasma concentrations. TDDS circumvent these issues by offering improved systemic drug availability, reduced side effects, and improved patient compliance. Thus, the following chapter covers recent developments in biosensing technology in transdermal drug delivery for the management of various diseases. © 2025 Elsevier Inc. All rights reserved.